{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:12:35Z","timestamp":1790730755226,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,6,16]],"date-time":"2016-06-16T00:00:00Z","timestamp":1466035200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"FDA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"FDA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006229","name":"Oak Ridge Institute for Science and Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006229","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"FDA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"FDA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.drudis.2016.06.006","type":"journal-article","created":{"date-parts":[[2016,6,16]],"date-time":"2016-06-16T02:16:18Z","timestamp":1466043378000},"page":"1566-1570","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["FDA drug labeling: rich resources to facilitate precision medicine, drug safety, and regulatory science"],"prefix":"10.1016","volume":"21","author":[{"given":"Hong","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen C.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhichao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangxu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilliam","family":"Rosario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weida","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2016.06.006_bib0110","series-title":"Promoting Safe and Effective Drugs for 100 Years","author":"FDA","year":"2006"},{"key":"10.1016\/j.drudis.2016.06.006_bib0115","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1146\/annurev.pharmtox.41.1.347","article-title":"Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies","volume":"41","author":"Lesko","year":"2001","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.drudis.2016.06.006_bib0120","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1001\/jama.290.7.905","article-title":"Pediatric drug labeling: improving the safety and efficacy of pediatric therapies","volume":"290","author":"Roberts","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.drudis.2016.06.006_bib0125","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-pharmtox-011112-140159","article-title":"One hundred years of drug regulation: where do we go from here?","volume":"53","author":"Woosley","year":"2013","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.drudis.2016.06.006_bib0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2105-13-S15-S6","article-title":"Investigating drug repositioning opportunities in FDA drug labels through topic modeling","volume":"13","author":"Bisgin","year":"2012","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.drudis.2016.06.006_bib0135","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/msb.2009.98","article-title":"A side effect resource to capture phenotypic effects of drugs","volume":"6","author":"Kuhn","year":"2010","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.drudis.2016.06.006_bib0140","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/tpj.2014.86","article-title":"Pharmacogenomic information in drug labels: European Medicines Agency perspective","volume":"15","author":"Ehmann","year":"2015","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.drudis.2016.06.006_bib0145","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1592\/phco.28.8.992","article-title":"Pharmacogenomic biomarker information in drug labels approved by the United States Food and Drug Administration: prevalence of related drug use","volume":"28","author":"Frueh","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.drudis.2016.06.006_bib0150","doi-asserted-by":"crossref","first-page":"R58","DOI":"10.1093\/hmg\/dds341","article-title":"Pharmacogenomics of adverse drug reactions: implementing personalized medicine","volume":"21","author":"Wei","year":"2012","journal-title":"Human Mol. Genet."},{"key":"10.1016\/j.drudis.2016.06.006_bib0155","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1056\/NEJMp0911494","article-title":"The missing voice of patients in drug-safety reporting","volume":"362","author":"Basch","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2016.06.006_bib0160","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nrd3946","article-title":"2012 FDA drug approvals","volume":"12","author":"Mullard","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drudis.2016.06.006_bib0165","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/clpt.2013.109","article-title":"Are drug labels static or dynamic?","volume":"94","author":"Seminerio","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.drudis.2016.06.006_bib0170","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1001\/jamainternmed.2014.5266","article-title":"Clinical evidence supporting pharmacogenomic biomarker testing provided in US Food and Drug Administration drug labels","volume":"174","author":"Wang","year":"2014","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.drudis.2016.06.006_bib0175","series-title":"Guidance for Industry on Clinical Pharmacogenomics Information Preparation for Labeling","author":"FDA","year":"2013"},{"key":"10.1016\/j.drudis.2016.06.006_bib0180","first-page":"110","article-title":"HL7 structured product labeling-electronic prescribing information for provider order entry decision support","volume":"2005","author":"Schadow","year":"2005","journal-title":"AMIA Annu. Symp. Proc."},{"key":"10.1016\/j.drudis.2016.06.006_bib0185","first-page":"646","article-title":"Assessing the impact of HL7\/FDA Structured Product Label (SPL) content for medication knowledge management","volume":"2007","author":"Schadow","year":"2007","journal-title":"AMIA Annu. Symp. Proc."},{"key":"10.1016\/j.drudis.2016.06.006_bib0190","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.drudis.2011.05.007","article-title":"FDA-approved drug labeling for the study of drug-induced liver injury","volume":"16","author":"Chen","year":"2011","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drudis.2016.06.006_bib0195","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B*5701 screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2016.06.006_bib0200","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1001\/jama.287.17.2215","article-title":"Timing of new black box warnings and withdrawals for prescription medications","volume":"287","author":"Lasser","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.drudis.2016.06.006_bib0205","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/toxsci\/kft189","article-title":"Quantitative structure\u2013activity relationship models for predicting drug-induced liver injury based on FDA-approved drug labeling annotation and using a large collection of drugs","volume":"136","author":"Chen","year":"2013","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.drudis.2016.06.006_bib0210","doi-asserted-by":"crossref","first-page":"e1002310","DOI":"10.1371\/journal.pcbi.1002310","article-title":"Translating clinical findings into knowledge in drug safety evaluation \u2013 Drug Induced Liver Injury Prediction System (DILIps)","volume":"7","author":"Liu","year":"2011","journal-title":"PLoS Comput. Biol."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644616302240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644616302240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:25:56Z","timestamp":1761222356000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644616302240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S1359644616302240"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2016.06.006","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FDA drug labeling: rich resources to facilitate precision medicine, drug safety, and regulatory science","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2016.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}